Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sustained virological response in chronic hepatitis C patients after a 6- and a 36-month interferon-alpha2b treatment schedule: a multicenter, randomized, controlled study.
Damen M, Weegink CJ, Mauser-Bunschoten EP, Cuypers HT, Hermus MC, Sillekens P, Haan E, van den Berg HM, Bresters D, Lelie PN, Chamuleau RA, Reesink HW. Damen M, et al. Among authors: reesink hw. Scand J Gastroenterol. 2001 Jan;36(1):97-104. doi: 10.1080/00365520150218129. Scand J Gastroenterol. 2001. PMID: 11218246 Clinical Trial.
New developments in the antiviral treatment of hepatitis C.
de Bruijne J, Weegink CJ, Jansen PL, Reesink HW. de Bruijne J, et al. Among authors: reesink hw. Vox Sang. 2009 Jul;97(1):1-12. doi: 10.1111/j.1423-0410.2009.01187.x. Epub 2009 Apr 20. Vox Sang. 2009. PMID: 19392783 Free PMC article. Review.
New developments in antiviral therapy for chronic hepatitis B.
Takkenberg RB, Weegink CJ, Zaaijer HL, Reesink HW. Takkenberg RB, et al. Among authors: reesink hw. Vox Sang. 2010 May;98(4):481-94. doi: 10.1111/j.1423-0410.2009.01282.x. Epub 2009 Nov 25. Vox Sang. 2010. PMID: 19951307 Review.
Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir.
de Niet A, Takkenberg RB, Benayed R, Riley-Gillis B, Weegink CJ, Zaaijer HL, Koot M, Jansen PL, Beld MG, Lopatin U, Reesink HW. de Niet A, et al. Among authors: reesink hw. Scand J Gastroenterol. 2012 Apr;47(4):475-81. doi: 10.3109/00365521.2011.648952. Epub 2012 Jan 23. Scand J Gastroenterol. 2012. PMID: 22263608 Clinical Trial.
Chronic hepatitis E after solid organ transplantation.
de Niet A, Zaaijer HL, ten Berge I, Weegink CJ, Reesink HW, Beuers U. de Niet A, et al. Among authors: reesink hw. Neth J Med. 2012 Aug;70(6):261-6. Neth J Med. 2012. PMID: 22859417 Free article.
Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor.
de Bruijne J, Thomas XV, Rebers SP, Weegink CJ, Treitel MA, Hughes E, Bergmann JF, de Knegt RJ, Janssen HL, Reesink HW, Molenkamp R, Schinkel J. de Bruijne J, et al. Among authors: reesink hw. J Viral Hepat. 2013 Nov;20(11):779-89. doi: 10.1111/jvh.12104. Epub 2013 Jun 27. J Viral Hepat. 2013. PMID: 24168257 Clinical Trial.
Novel therapies in hepatitis B and C.
Takkenberg B, de Bruijne J, Weegink C, Jansen P, Reesink H. Takkenberg B, et al. Curr Gastroenterol Rep. 2008 Feb;10(1):81-90. doi: 10.1007/s11894-008-0013-z. Curr Gastroenterol Rep. 2008. PMID: 18417047 Review.
Safety and antiviral activity of JTK-652: a novel HCV infection inhibitor.
de Bruijne J, Bergmann JF, Weegink CJ, van Nieuwkerk CM, de Knegt RJ, Komoda Y, van de Wetering de Rooij JJ, van Vliet A, Jansen PL, Molenkamp R, Schinkel J, Reesink H, Janssen HL. de Bruijne J, et al. Antivir Ther. 2010;15(5):765-73. doi: 10.3851/IMP1606. Antivir Ther. 2010. PMID: 20710058 Clinical Trial.
353 results